Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 260

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 260
---
 with an involuntary petition against it in any insolvency
proceeding and such involuntary petition has not been stayed or dismissed within 90 days after its filing, or (c) makes an assignment of substantially all of its assets for the benefit of its creditors.

The Romeg License Agreement contains customary reciprocal indemnification obligations for Romeg and us. Additionally, we agreed, subject to
certain exceptions, to indemnify Romeg against any loss arising out of the manufacture or commercialization of any Licensed Product by or on behalf of us or our affiliates, marketing partners, sublicensees or subcontractors on or after the date of
the license.

The foregoing is a summary of the material terms of the Romeg License Agreement (including the amendment thereto) in the
forms filed as exhibits to this prospectus. You should read the form of the agreements for a complete understanding of all of their terms.

Lifecore Master Services Agreement

On January 27, 2017, through our wholly owned subsidiary, Semnur, we entered into that certain
Master Services Agreement (as amended, the “Lifecore Master Services Agreement”), with Lifecore Biomedical, LLC (“Lifecore”). Pursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial material
manufacturing and development services for SEMDEXA as set forth in each separate statement of work (each a “Lifecore Statement of Work”).

174

The parties entered into a Lifecore Statement of Work on January 27, 2017, pursuant to
which Lifecore agreed to provide, among other things, (1) project management support, (2) development services, (3) clinical trial materials, and (4) stability studies. We paid Lifecore for the development and clinical trial
material manufacturing services, which was invoiced at the completion of each service.

For the purposes of Lifecore’s development
and clinical trial material manufacturing obligations, we granted Lifecore a nonexclusive, worldwide and royalty-free license under our owned or controlled intellectual property rights necessary to manufacture
SP-102, without additional right, title or interest in our intellectual property.

The Lifecore
Master Services Agreement expires on December 31, 2028, unless terminated earlier in accordance with the terms of such agreement, or unless renewed further by the parties. Either party may terminate the Lifecore Master Services Agreement
(1) if the other party is in material breach of the agreement and